Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,856 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Magnetic Resonance Clear all

Conditions: Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Breast Cancer
Interventions: PEM Flex Solo II PET Scanner, MRI scan; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions: Biospecimen Collection, Bone Scan, Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Drug · Other + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Stroke, Muscle Spasticity
Interventions: Botox (botulinum toxin); Drug
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Spinal Cord Injuries
Interventions: Magnetic Resonance Imaging (MRI); Diagnostic Test
Lead sponsor: Lineage Cell Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 3
States / cities: Palo Alto, California • Atlanta, Georgia • Evanston, Illinois

Conditions: Breast Cancer
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more

Conditions: Coronary Disease
Interventions: Coronary magnetic resonance angiography imaging; Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Schizophrenia
Interventions: [11C]UCB-J radiotracer, PET-MR; Drug · Device
Lead sponsor: Davidzon, Guido, M.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Hepatocellular Carcinoma (HCC), Liver Cirrhosis
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma, Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Diffusing Alpha-emitter Radiation Therapy, Docetaxel, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Modified Barium Swallow Study, Observation Activity, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire; Procedure · Drug · Radiation + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Ulixertinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypoglycemia, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 20 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atrial Fibrillation
Interventions: DE-MRI; Procedure
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 339 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 5
States / cities: Tampa, Florida • Chicago, Illinois • Columbus, Ohio + 2 more

Conditions: Coronary Artery Disease, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Angina
Interventions: Regadenoson, Dobutamine; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Type 1 Diabetes
Interventions: ferumoxytol; Drug
Lead sponsor: Jason Gaglia; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Heart Failure, Congestive
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 55 Years to 85 Years
Enrollment: 579 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Depressive Disorder, Major, Post Traumatic Stress Disorder
Interventions: Ketamine, Perampanel, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urinary Bladder Neoplasms
Interventions: Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM); Diagnostic Test · Drug
Lead sponsor: Jodi Maranchie; Other
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COPD, Cystic Fibrosis, Asthma, Healthy
Interventions: Hyperpolarized Helium-3; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 5 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm, Unresectable Melanoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Dabrafenib Mesylate, Magnetic Resonance Imaging, Trametinib Dimethyl Sulfoxide, Uprosertib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more

Conditions: Type 2 Diabetes, BMI Greater Than 30
Interventions: 31P-MRS and MRI; Radiation
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 45 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Aging
Interventions: Aerobic Exercise, Non-Aerobic Exercise; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioblastoma
Interventions: Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging, Radiation Therapy, Surgical Procedure, Temozolomide; Procedure · Radiation · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

Exploring Advanced Imaging Techniques to Characterize Botulinum Toxin Diffusion in Human Muscle

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

LTFU Study of Subjects Who Received GRNOPC1

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

Safety and Effectiveness of Coronary Magnetic Resonance Angiography (CMRA) Imaging

Imaging Synapses With [11C] UCB-J in the Human Brain

FAST (Focused Abbreviated Screening Technique)-MRI Study

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Hippocampal Metabolism and Function in Patients With Type 1 Diabetes

DECAAF: Delayed-Enhancement MRI (DE-MRI) Determinant of Successful Radiofrequency Catheter Ablation of Atrial Fibrillation

Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)

Imaging of Type 1 Diabetes Progression

Using Magnetic Resonance Imaging to Predict People Who Are Likely to Develop Flash Pulmonary Edema (The PREDICT Study)

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Imaging in Semaglutide Study

Neuroimaging Study of Exercise and Memory Function

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma